Sun Pharma’s Q2FY26 results showed a 2.56% YoY increase in net profit and a 9.6% increase in revenue. On a sequential basis, net profit jumped 36.83% and revenue surged 4.53%. EBITDA stood at Rs. 4,527.1 crore with a margin of 31.3%. R&D investment was 5.4% of sales. Formulation sales in India saw a growth of 11%.